Patients with HC iron had lower serum insulin and HOMA-IR levels, suggesting that the development of steatosis among these patients might be secondary to cytotoxic injury from HC iron, uncovering a distinct phenotype of MASLD among these patients. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.